We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

NanoAssemblr™ Chosen for Horizon 2020 Project to Develop Novel RNA therapeutics

Product News   Mar 29, 2017 | Original story from Precision Nanosystems

 
NanoAssemblr™ Chosen for Horizon 2020 Project to Develop Novel RNA therapeutics

Credit: Precision NanoSystems

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BV100

Product News

BioVersys has reached a major milestone by entering clinical development with the start of Phase 1 testing of BV100 in healthy volunteers.

READ MORE

Abcam’s New Premium-Grade Bioactive Proteins, for Drug Discovery, Development and Manufacturing

Product News

Abcam’s new premium-grade proteins are manufactured in mammalian cell lines under animal-free conditions limiting endotoxins to ultra-low levels (< 5 EU/mg).

READ MORE

CatSci Further Strengthens its Customer-Focused Strategic Advisory Board

Product News

CatSci has appointed three key industry thought leaders to its Strategic Advisory Board.

READ MORE

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE